PB1890: ZANUBRUTINIB IN ACALABRUTINIB-INTOLERANT PATIENTS (PTS) WITH B-CELL MALIGNANCIES

• M. Shadman,
• I. W. Flinn,
• E. C. Kingsley,
• B. Freeman,
• M. Y. Levy,
• J. Cultrera,
• C. M. Farber,
• A. Chaudhry,
• R. Porter,
• R. Crescenzo,
• A. Idoine,
• X. Zhang,
• A. Cohen,
• K. By,
• J. Huang,
• J. P. Sharman

Affiliations

M. Shadman

1 Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA

I. W. Flinn

2 Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN

E. C. Kingsley

3 Comprehensive Cancer Centers of Nevada, Las Vegas, NV

B. Freeman

4 Summit Medical Group, Florham Park, NJ

M. Y. Levy

5 Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

J. Cultrera

6 Florida Cancer Specialists & Research Institute, Leesburg, FL

C. M. Farber

7 Atlantic Hematology Oncology, Morristown Medical Center, Morristown, NJ

A. Chaudhry

8 Summit Cancer Centers, Spokane, WA

R. Porter

9 SSM Health Dean Medical Group, Madison, WI

R. Crescenzo

10 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA

A. Idoine

10 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA

X. Zhang

10 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA

A. Cohen

10 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA

K. By

10 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA

J. Huang

10 BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA

J. P. Sharman

11 Willamette Valley Cancer Institute and Research Center, Eugene, OR, United States of America